Home / Treatments / Gamunex-c
Gamunex-c denials: what the review data shows
Independent reviewers have decided 22 published cases where an insurer denied Gamunex-c — and they overturned the insurer 68.2% of the time. A denial for Gamunex-c is a starting position, not a final answer.
Published decisions
22
2001–2026
Overturned
68.2%
15 denials reversed
Conditions behind gamunex-c denials
What insurers denied — and how those fights ended.
| Category | Decisions | Overturned |
|---|---|---|
| Small Fiber Polyneuropathy | 3 | 66.7% |
What the insurer actually argued
Denials fall into different categories, and they don’t succeed equally — so the reason on your letter changes how you should answer it.
| Reason given | Decisions | Overturned |
|---|---|---|
Medical Necessity The plan said the care wasn’t medically necessary. The most common fight, and the most winnable. | 18 | 66.7% |
Experimental/Investigational The plan called the treatment unproven. These turn on published evidence, so the appeal is a literature argument. | 4 | 75% |
Typical time to a decision
7 days
Most land between 3 and 16 days
Handled as urgent
72.7%
Expedited when a delay would cause harm
What the reviewers wrote
Excerpts from the independent reviewers’ published findings — the actual reasoning, quoted, not summarised.
Where the denial was overturned
Nature of Statutory Criteria/Case Summary: An enrollee has requested authorization and coverage for Gamunex-C immune globulin injection (IVIG). Dysautonomia is an umbrella term referring to any disorder associated with dysfunction of the autonomic nervous system. There are many different mechanisms by which dysautonomia may arise, but there has been increasing evidence and awareness that it may be immune-mediated in some patients. Autoimmune autonomic dysfunction may be peripheral due to an immune-mediated small fiber polyneuropathy (SFPN) and may manifest clinically as postural tachycardia syndrome, orthostatic intolerance, orthostatic hypotension, inappropriate sinus tachycardia, gastrointestinal dysmotility, complex regional pain syndrome, and/or neurogenic bladder.
Nature of Statutory Criteria/Case Summary: The patient requested authorization and coverage for Gamunex-C (immune globulin, IVIG).Gamunex-C (immune globulin intravenous, IVIG) is an appropriate treatment option for patients with a history of autoimmune encephalitis in the setting of primary immunodeficiency and complement deficiency. Additionally, Gamunex-C is indicated for the treatment of primary immunodeficiency diseases. IVIG therapy is commonly used to treat autoimmune neurological disorders, including autoimmune encephalitis, by providing antibodies that help modulate the immune system and reduce inflammation in the central nervous system. IVIG can help replace missing or deficient antibodies and provide passive immunity against infections.
Where the denial was upheld
Worth reading too — these show what an appeal has to overcome.
Findings: The physician reviewer found that Nature of Statutory Criteria/Case Summary: The patient’s parent has requested authorization and coverage for intravenous immunoglobulins (IVIG) therapy, Gamunex-C vial. Current medical literature offers limited data to support IVIG use in epilepsy. Overall, IVIG has not been demonstrated to be effective in the treatment of epilepsy and is most likely effective in patients with autoimmune encephalitis. According to one study, there is a lack of controlled trials to support IVIG use in electrical status epilepticus in sleep (ESES). One clinical study showed that children with GRIN2A and GRIN2D mutation related to ESES showed some improvement with IVIG but remained significantly developmentally impaired. In this case, the patient has ESES and possible Landau Kleffner syndrome of unknown etiology.
Nature of Statutory Criteria/Case Summary: The patient has requested authorization and coverage for Gamunex-C. Small fiber polyneuropathy occurs because of injury to the small unmyelinated C or thinly myelinated nerve fibers, and causes symptoms of numbness, sensory loss, electric shock-like pain, cold-like pain, itching, burning, tingling, and pins and needles feeling. The first line treatment for small fiber neuropathy includes tricyclic antidepressants (TCAs) such as amitriptyline, nortriptyline, and clomipramine, serotonin and norepinephrine reuptake inhibitors (SNRIs), and anticonvulsants such as duloxetine, gabapentin, and pregabalin. In this case, the patient was diagnosed with a small fiber neuropathy secondary to inflammatory or post-infection, with symptoms of tingling and burning pain in her extremities, sensitivity to cold temperature, and difficulty ambulating.
Figures and quotations on this page come from 42,749 published decisions in the California DMHC Independent Medical Review dataset. These are California outcomes — every state runs an equivalent external review, but the rates here are California’s. Excerpts are quoted verbatim from the public record and describe this treatment generally, not any individual case.
How to use this in your appeal
These are outcomes from California’s external review program — an independent physician panel that binds the insurer. Every state has an equivalent process, and internal appeals succeed even more often. Cite the outcome record for Gamunex-cwhen you appeal: reviewers routinely find that denials like yours didn’t hold up.
SOURCE: CALIFORNIA DMHC INDEPENDENT MEDICAL REVIEW OUTCOMES (CHHS OPEN DATA) · DERIVED AGGREGATE STATISTICS ONLY · METHODOLOGY
Not legal or medical advice. Coverage Rights is a self-help tool that helps you prepare your own appeal. For advice about your specific situation, talk to a licensed attorney or your doctor.